MWNA
INFI

Marshall Wace North America’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Marshall Wace North America’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-367,031
Closed -$701K – 1475
2018
Q2 		$701K Sell
367,031
-414,305
-53% -$837K ﹤0.01% 1019
2018
Q1 		$1.64M Sell
781,336
-392,179
-33% -$841K 0.01% 860
2017
Q4 		$2.38M Buy
+1,173,515
New +$2.43M 0.01% 793

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Marshall Wace North America's INFI Position: Q3 2018 in Review

Marshall Wace North America sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2018, closing a stake of 367,031 shares — an estimated $701K sold.

Marshall Wace North America first reported a position in INFI in Q4 2017 and held it in 3 quarters. The position peaked at $2.38M in Q4 2017. 63 funds tracked by Wall St. Rank hold INFI as of Q3 2018.

  • Marshall Wace North America reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Marshall Wace North America sold 367,031 Infinity Pharmaceuticals, Inc. shares in Q3 2018, an estimated $701K.
  • Marshall Wace North America first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
  • Marshall Wace North America's Infinity Pharmaceuticals, Inc. position peaked at $2.38M in Q4 2017.
  • 63 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2018.

Based on Marshall Wace North America's 13F filing for Q3 2018, filed 14 Nov 2018.